Journal: Oncology Letters

Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis

doi: 10.3892/ol.2026.15551

Figure Lengend Snippet: Sch B inhibits NF-κB signaling pathway expression. mRNA expression levels of (A) IL-6, (B) IL-8 (C) and TNF-α were measured in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). Statistical analysis was performed using Welch's ANOVA followed by Dunnett's T3 post hoc test. (D) NF-κB expression in CCA cells was evaluated using a double luciferase assay with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l). (E) Hoechst immunofluorescence staining of p65 expression in CCA cells. (F) CCA cell activity was assessed after treatment with Sch B and Bay 11–7082, a targeted NF-κB inhibitor. Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. Sch B, Schisandrin B; CCA, cholangiocarcinoma.

Article Snippet: p-p65 NF-κB (Ser536) , 3033 , 1:1,000 , Cell Signaling Technology, Inc..

Techniques: Expressing, Luciferase, Immunofluorescence, Staining, Activity Assay

Journal: Journal of Advanced Research

Article Title: Tussilagone attenuated cigarette smoke-induced chronic obstructive pulmonary disease through regulating Nrf2 and NF-κB/NLRP3 inflammasome via directly targeting cysteine 434 of KEAP1

doi: 10.1016/j.jare.2025.07.019

Figure Lengend Snippet: TUS inhibited NF-κB by activating Nrf2. (A) The protein levels of p -NF-κB, IκB, iNOS, and COX-2 in the RAW 264.7 cells treated with 1 μg/mL LPS and TUS at 2.5, 5, 10, and 20 μM. (B) The regulation of TUS on p -NF-κB levels in the cytoplasm and nucleus. RAW 264.7 cells treated with 1 μg/mL LPS and TUS at 10 and 20 μM for 8 h, and the protein level of p -NF-κB in the cytoplasm and nucleus were detected using Western blot. (C) Immunofluorescence indicated that TUS inhibited p -NF-κB translocation into the nucleus. RAW 264.7 cells were treated with 1 μg/mL LPS and TUS at 10 and 20 μM for 8 h, followed by incubation with p -NF-κB primary antibody and Alex 594 secondary antibody. The immunofluorescence of p -NF-κB was observed and imaged. (D-E) The regulatory effects of TUS on protein levels of p -NF-κB, IκB, iNOS, and COX-2 in the WT and Nrf2-silenced RAW 264.7 cells. WT and Nrf2-silenced RAW 264.7 cells were treated with 10 μM TUS, and the protein levels of p -NF-κB, iNOS, and COX-2 were detected using Western blot. (F) The regulatory effects of TUS on protein levels of iNOS and COX-2 in the WT or C434A mutant RAW 264.7 cells. WT and C434A mutant RAW 264.7 cells were treated with 10 μM TUS, and the protein levels of p -NF-κB, iNOS, and COX-2 were detected using Western blot. The results were expressed as mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 treated vs LPS group.

Article Snippet: The Antibodies for p- NF-κB (3033, 1:2000) was purchased from cell signaling technology (Danvers, MA, USA).

Techniques: Western Blot, Immunofluorescence, Translocation Assay, Incubation, Mutagenesis

Journal: Journal of Advanced Research

Article Title: Tussilagone attenuated cigarette smoke-induced chronic obstructive pulmonary disease through regulating Nrf2 and NF-κB/NLRP3 inflammasome via directly targeting cysteine 434 of KEAP1

doi: 10.1016/j.jare.2025.07.019

Figure Lengend Snippet: TUS inhibited lung inflammation by activating Nrf2. (A) The images of lung tissues stained by H&E in indicated groups. (B-E) The levels of TNF-α and IL-1β in BALF of different groups. (F) The protein levels of Nrf2, iNOS, p -NF-κB, and IL-1β in the homogenate of lung tissues in indicated groups. (G) The mRNA levels of NF-κB, iNOS, NLRP3, COX-2, TNF-α, and IL-1β in the homogenate of lung tissues in indicated groups. The results were expressed as mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 treated vs LPS group.

Article Snippet: The Antibodies for p- NF-κB (3033, 1:2000) was purchased from cell signaling technology (Danvers, MA, USA).

Techniques: Staining